ArticleFrontiers in systems biology2026
Toward the genetic landscape of prostate cancer in India: insights from whole-exome and low-pass whole-genome sequencing of formalin-fixed paraffin-embedded tumor tissues.
Article in Frontiers in systems biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prostate cancer (PCa) is a leading malignancy in men, with global incidence showing geographical variations. In India, PCa burden is increasing, especially in urban areas and for men over 50 years of age. Our collaborative effort with the Cancer Prostate Consortium of India (CAPCI) aims to map the genetic landscape of PCa in India, investigate somatic mosaicism, and assess the utility of low-pass whole-genome sequencing (LP-WGS) in determining PCa pathogenesis. Materials and methods: We performed variant calling using the CONVEX pipeline on whole-exome sequencing (WES) and LP-WGS samples, categorized by tumor grades. Results and discussion: ClinVar validation of WES variants identified 12 consensus somatic variants mapped to gnomAD, with 11 being pathogenic, likely pathogenic, or variants of uncertain significance (VUS). We also screened 956 germline variants common to at least two of the 49 samples, identifying 88 common variants, including missense and small InDels. Common and unique somatic variants were found in APC, BRAF, ATM, TP53, SMAD4 and CHEK2 genes. Four of these (rs62619935, rs202160435, rs121913343, and rs141568342) are extremely rare (MAF <= 0.001), seven single nucleotide variants (SNVs) are novel, with four being VUS. Pathogenic somatic variants in higher Gleason score samples (4+4 and 4+3) were homozygous, while benign prostatic hyperplasia (BPH) samples with lower Gleason scores were heterozygous, aligning with population stratification. Whereas the rs1042522 variant in the TP53 gene, with a gnomAD MAF of nearly 38%, was a common somatic SNV, we also identified distinct CAG repeat mosaicism associated with PCa risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.